CARLSBAD, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ:SGNL) (Signal or the Company), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced that Samuel D. Riccitelli, President and CEO, will present a corporate overview at the 8th Annual LD Micro Main Event on December 3, 2015.
Event: 8th Annual LD Micro Main Event
Date: Thursday, December 3, 2015
Time: 11:30 a.m. PT
Location: Luxe Sunset Hotel - Los Angeles, CA
About Signal Genetics, Inc.
Signal Genetics, Inc., headquartered in Carlsbad, California, is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. Signal's mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions. Signal was founded in January 2010 and became the exclusive licensee in its licensed field to the renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences, in April 2010.